These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Exploiting Honokiol-induced ER stress CHOP activation inhibits the growth and metastasis of melanoma by suppressing the MITF and β-catenin pathways. Chiu CS; Tsai CH; Hsieh MS; Tsai SC; Jan YJ; Lin WY; Lai DW; Wu SM; Hsing HY; Arbiser JL; Sheu ML Cancer Lett; 2019 Feb; 442():113-125. PubMed ID: 30391358 [TBL] [Abstract][Full Text] [Related]
44. Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90. Bussenius J; Blazey CM; Aay N; Anand NK; Arcalas A; Baik T; Bowles OJ; Buhr CA; Costanzo S; Curtis JK; DeFina SC; Dubenko L; Heuer TS; Huang P; Jaeger C; Joshi A; Kennedy AR; Kim AI; Lara K; Lee J; Li J; Lougheed JC; Ma S; Malek S; Manalo JC; Martini JF; McGrath G; Nicoll M; Nuss JM; Pack M; Peto CJ; Tsang TH; Wang L; Womble SW; Yakes M; Zhang W; Rice KD Bioorg Med Chem Lett; 2012 Sep; 22(17):5396-404. PubMed ID: 22877636 [TBL] [Abstract][Full Text] [Related]
45. Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma. Patel A; Garcia LF; Mannella V; Gammon L; Borg TM; Maffucci T; Scatolini M; Chiorino G; Vergani E; Rodolfo M; Maurichi A; Posch C; Matin RN; Harwood CA; Bergamaschi D Cancer Res; 2020 Jun; 80(12):2676-2688. PubMed ID: 32291316 [TBL] [Abstract][Full Text] [Related]
46. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. Booth L; Roberts JL; Sander C; Lee J; Kirkwood JM; Poklepovic A; Dent P Oncotarget; 2017 Mar; 8(10):16367-16386. PubMed ID: 28146421 [TBL] [Abstract][Full Text] [Related]
48. Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma. Calero R; Morchon E; Martinez-Argudo I; Serrano R Cancer Lett; 2017 Oct; 406():1-11. PubMed ID: 28774796 [TBL] [Abstract][Full Text] [Related]
49. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Du J; Widlund HR; Horstmann MA; Ramaswamy S; Ross K; Huber WE; Nishimura EK; Golub TR; Fisher DE Cancer Cell; 2004 Dec; 6(6):565-76. PubMed ID: 15607961 [TBL] [Abstract][Full Text] [Related]
50. MITF Modulates Therapeutic Resistance through EGFR Signaling. Ji Z; Erin Chen Y; Kumar R; Taylor M; Jenny Njauw CN; Miao B; Frederick DT; Wargo JA; Flaherty KT; Jönsson G; Tsao H J Invest Dermatol; 2015 Jul; 135(7):1863-1872. PubMed ID: 25789707 [TBL] [Abstract][Full Text] [Related]
51. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma. Jalili A; Wagner C; Pashenkov M; Pathria G; Mertz KD; Widlund HR; Lupien M; Brunet JP; Golub TR; Stingl G; Fisher DE; Ramaswamy S; Wagner SN J Natl Cancer Inst; 2012 Nov; 104(21):1673-9. PubMed ID: 22997239 [TBL] [Abstract][Full Text] [Related]
52. How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance. Wessely A; Steeb T; Berking C; Heppt MV Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071193 [TBL] [Abstract][Full Text] [Related]
53. The Broad Stroke of Hsp90 Inhibitors: Painting over the RAF Inhibitor Paradox. Vido MJ; Aplin AE J Invest Dermatol; 2015 Oct; 135(10):2355-2357. PubMed ID: 26358385 [TBL] [Abstract][Full Text] [Related]
54. Global view of the RAF-MEK-ERK module and its immediate downstream effectors. Santini CC; Longden J; Schoof EM; Simpson CD; Jeschke GR; Creixell P; Kim J; Wu X; Turk BE; Rosen N; Poulikakos PI; Linding R Sci Rep; 2019 Jul; 9(1):10865. PubMed ID: 31350469 [TBL] [Abstract][Full Text] [Related]
55. Regulatory and functional connection of microphthalmia-associated transcription factor and anti-metastatic pigment epithelium derived factor in melanoma. Fernández-Barral A; Orgaz JL; Baquero P; Ali Z; Moreno A; Tiana M; Gómez V; Riveiro-Falkenbach E; Cañadas C; Zazo S; Bertolotto C; Davidson I; Rodríguez-Peralto JL; Palmero I; Rojo F; Jensen LD; del Peso L; Jiménez B Neoplasia; 2014 Jun; 16(6):529-42. PubMed ID: 25030625 [TBL] [Abstract][Full Text] [Related]
56. Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populations. Hartman ML; Talar B; Sztiller-Sikorska M; Nejc D; Czyz M Oncotarget; 2016 Feb; 7(8):9026-40. PubMed ID: 26824319 [TBL] [Abstract][Full Text] [Related]
57. The MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors. Liguoro D; Frigerio R; Ortolano A; Sacconi A; Acunzo M; Romano G; Nigita G; Bellei B; Madonna G; Capone M; Ascierto PA; Mancini R; Ciliberto G; Fattore L Cell Death Dis; 2024 Mar; 15(3):208. PubMed ID: 38472212 [TBL] [Abstract][Full Text] [Related]